CEL-SCI Corp (CEL-SCI) is a late clinical-stage biotechnology company. It is focused on research and development aimed at improving cancer treatment and other diseases by leveraging the immune system. The company's primary focus is its lead product, Multikine, which has undergone a global Phase III trial involving 928 patients for the treatment of advanced primary squamous cell carcinoma of the head and neck. Additionally, CEL-SCI is developing LEAPS-based peptide candidates, such as CEL-2000 and CEL-4000, aimed at addressing rheumatoid arthritis. The company operates within various sectors, including biotechnology, oncology, immunology, and infectious disease.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's research and development initiatives focus on two main projects: Multikine and LEAPS. Multikine is an investigational immunotherapy under development for the potential treatment of advanced primary head and neck cancer. LEAPS is a platform technology with two investigational product candidates under development for the potential treatment of rheumatoid arthritis. The company has not received approval from the FDA or any other regulatory agency for the sale, barter, or exchange of these products, and their safety or efficacy has not been established for any use. The R&D units of the company are Multikine and LEAPS, which are responsible for managing the development of investigational therapies for specific medical conditions. In FY2025, the company spent US$15.9 million on R&D.